Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases

Fordy, C; Glover, Clare; Davies, Michael M.; Allen-Mersh, T G

doi:10.1038/bjc.1998.627

Cited by 18 publications

(7 citation statements)

References 22 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this regard, this study suggests floxuridine (CAS: 50-91-9) as a promising candidate with dual actions, since its MIC value against MRSA was found to be within the low nanomolar range (Table 2). It is well known that floxuridine is a prodrug that has to be converted in vivo into 5-fluorouracil or the corresponding monophosphate form to exert its cytotoxic effect [12]. This piece of information is valuable from a drug design point of view, since medicinal chemists can structurally optimize floxuridine to prevent human in vivo activation while maintaining bacterial deoxyribonucleoside kinases specific activation [13].…”

Section: Resultsmentioning

confidence: 99%

In Vitro Screening of an FDA-Approved Library Against ESKAPE Pathogens

Younis

AbdelKhalek

Mayhoub

et al. 2017

CPD

View full text Add to dashboard Cite

Bacterial resistance to conventional antibiotics is an increasingly serious threat to public health worldwide that requires immediate exploration and the development of novel antimicrobial compounds. Drug repurposing is an inexpensive and untapped source of new antimicrobial leads, and it holds many attractive features warranting further attention for antimicrobial drug discovery. In an effort to repurpose drugs and explore new leads in the field of antimicrobial drug discovery, we performed a whole-cell screening assay of 1,600 Food and Drug Administration (FDA) approved drugs against Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter cloacae (ESKAPE) pathogens. The in vitro screening identified 49 non-antimicrobial drugs that were active against at least one species of ESKAPE pathogen. Although some of these drugs were known to have antibacterial activity, many have never been reported before. In particular, sulfonamide-containing structures represent a novel drug scaffold that should be investigated further. The characteristics of these drugs as antimicrobial agents may offer a safe, effective, and quick supplement to current approaches to treating bacterial infections.

show abstract

Section: Resultsmentioning

confidence: 99%

In Vitro Screening of an FDA-Approved Library Against ESKAPE Pathogens

Younis

AbdelKhalek

Mayhoub

et al. 2017

CPD

View full text Add to dashboard Cite

show abstract

“…In previously treated patients in whom the disease progressed on 5-FU-based CT, the RR with HAI CT (including CPT-11 and oxaliplatin) was good (ranged from 14% to 64%) and the median survival exceeded 7-20 months [16,19,24,25,30,33]. HAI FUDR, however, was associated with significant hepatic toxicity and when combined with systemic CT troublesome systemic toxicity occurred [8,16,18,33]. The administration of newer CT via HA however reduced the risk of chronic hepatobiliary toxicity but was associated with systemic toxicity [16,28,30].…”

Section: Discussion Hepatic Artery Infusion Of Chemotherapy (Hai Ct)mentioning

confidence: 98%

Regional treatment of colorectal liver metastasis

Kulaylat

Gibbs

2010

Journal of Surgical Oncology

View full text Add to dashboard Cite

Compared to systemic chemotherapy, intraarterial administration of tumoricidal agents with or without systemic chemotherapy in the treatment of nonresectable metastatic colorectal cancer is associated with superior response rate. The time-to-hepatic progression is also increased but the effect on overall survival is variable. When combined with other treatment modalities the number of patients who benefit from the treatment increases. In a subgroup of patients with resectable disease, hepatic artery infusion of chemotherapy as adjuvant therapy may be beneficial. Progression of the disease, hepatic and systemic toxicity, and complexity of the surgical aspects of the treatment limit the routine use of this treatment modality.

show abstract

“…A better outcome and a prolonged maintenance of quality of life for patients treated with HAC compared to intravenous treatment were found [26, 31]. In patients who failed on prior systemic 5-FU-based chemotherapy, response rates observed with HAC are still 15–25%, with a median response duration on 6–7 months [23, 32, 33]. However, with the introduction of CPT-11 as effective systemic second-line treatment, HAC should probably not be the first choice of treatment in this setting [34, 35].…”

Section: Results and Complications Of Hacmentioning

confidence: 99%

Hepatic Arterial Chemotherapy for Colorectal Cancer Metastatic to the Liver

et al. 2000

View full text Add to dashboard Cite

In advanced colorectal cancer, liver metastases are a major problem. In patients with liver metastases as the major site of disease hepatic arterial chemotherapy is a valid alternative to systemic treatment. In this review about hepatic arterial chemotherapy we will discuss the theoretical and practical aspects, the results and complications, the selection of patients for hepatic arterial chemotherapy, and its future developments.

show abstract

Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases

Abstract: Summary Hepatic arterial floxundine (HAI) in 35 patients with systemic fluorouracilfolinic acid-resistant colorectal liver metastases achieved a 140o partial response and 260o disease stabilization rate. with a median response duration of 7 months from onset of HAI.

Cited by 18 publications

References 22 publications

In Vitro Screening of an FDA-Approved Library Against ESKAPE Pathogens

In Vitro Screening of an FDA-Approved Library Against ESKAPE Pathogens

Regional treatment of colorectal liver metastasis

Hepatic Arterial Chemotherapy for Colorectal Cancer Metastatic to the Liver

Contact Info

Product

Resources

About